Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.61 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL84181 | 0.98 | SKP2 (0.59) | SKP2TLR8TYRCA2SMN1; SMN2 | |
| SCHEMBL5830877 | 0.85 | HTR2A (0.53) | SKP2TLR8CA2HTR2A | |
| SCHEMBL2958383 | 0.85 | SKP2 (0.53) | SKP2TLR8CA2HTR1AHTR2A | |
| SCHEMBL8375841 | 0.84 | SKP2 (0.67) | SKP2TLR8CA2SMN1; SMN2HTR1A | |
| SCHEMBL27705882 | 0.84 | SKP2 (0.45) | SKP2TLR8TYRHPGD | |
| SCHEMBL7204931 | 0.83 | SKP2 (0.71) | SKP2CA2SMN1; SMN2HTR1AHTR2A | |
| SCHEMBL29511379 | 0.83 | SKP2 (0.71) | SKP2CA2SMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8781871 | 0.83 | SKP2 (0.46) | SKP2CA2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5830312 | 0.83 | HTR2A (0.47) | SKP2TLR8TYRSMN1; SMN2HTR2A | |
| SCHEMBL10492538 | 0.82 | TYR (0.46) | SKP2TLR8TYRHTR2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3396028-B1 | DIRECT ELECTROCHEMICAL SYNTHESIS OF DOPED CONDUCTIVE POLYMERS ON METAL ALLOYS | BOEING CO (US) | 2022-04-06 | — | — | EP | claimed |
| EP-2139977-A2 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | ExxonMobil Research and Engineering Company (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008123940-A2 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2008-10-16 | — | — | WO | claimed |
| US-7211202-B2 | Process to make a conductive composition of a fluorinated polymer which contains polyaniline | ATOFINA (FR) | 2007-05-01 | — | — | US | claimed |
| EP-1428857-B1 | Process to make a conductive composition of a fluorinated polymer which contains polyaniline | ARKEMA FRANCE (FR) | 2007-01-31 | — | — | EP | claimed |
| US-6764617-B1 | AND FERROMAGNETIC IRON OXIDE PARTICLES; ELECTROMAGNETIC SHIELDS; ACID RESISTANCE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS & SPACE ADMINISTRATION | 2004-07-20 | — | — | US | claimed |
| US-5968417-A | Conducting compositions of matter | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 1999-10-19 | — | — | US | claimed |
| US-5415893-A | Dispersion of electrically conductive particles in a dispersing medium | DSM N.V. (NL) | 1995-05-16 | — | — | US | claimed |
| US-11577212-B2 | Stimuli-responsive micro-reservoirs for release of encapsulants | SAS Nanotechnologies Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3396028-B1 | DIRECT ELECTROCHEMICAL SYNTHESIS OF DOPED CONDUCTIVE POLYMERS ON METAL ALLOYS | BOEING CO (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3823745-A1 | STIMULI-RESPONSIVE MICRO-RESERVOIRS FOR RELEASE OF ENCAPSULANTS | SAS Nanotechnologies LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020018555-A1 | STIMULI-RESPONSIVE MICRO-RESERVOIRS FOR RELEASE OF ENCAPSULANTS | SAS Nanotechnologies LLC (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-5456862-A | Thermally stable forms of electrically conductive polyaniline | ALLIEDSIGNAL INC. (US) | 1995-10-10 | — | — | US | disclosed |
| US-5415893-A | Dispersion of electrically conductive particles in a dispersing medium | DSM N.V. (NL) | 1995-05-16 | — | — | US | disclosed |
| EP-0589529-A1 | Dispersion of electrically conductive particles in a dispersing medium | DSM N.V. (NL) | 1994-03-30 | — | — | EP | disclosed |
| US-5278213-A | Low viscosity solution | ALLIED SIGNAL INC. (US) | 1994-01-11 | — | — | US | disclosed |
| US-5262483-A | Styrene-maleic anhydride and polyaniline grafted with processability and conductivity | DSM N.V. (NL) | 1993-11-16 | — | — | US | disclosed |
| EP-0538939-A1 | Polymer composition | DSM N.V. (NL) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | SKP2 4478/4885TLR8 4784/4885TYR 4844/4885 |
| US-11577212-B2 | Stimuli-responsive micro-reservoirs for release of encapsulants | ORAI1, CD44, VAPA | SKP2 3285/4885TLR8 1963/4885TYR 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.